| Company Announcements: (reported by the Company) |
No items found
|
| Elevator Pitch: | The AI Biotech Fund is a specialised, data-driven investment fund combining artificial intelligence and fundamental analysis to uncover mispriced opportunities in the biotech sector. We focus on companies approaching key clinical trial catalysts — where rigorous analysis and predictive modelling can create asymmetric outcomes. Our proprietary AI model incorporates Opyl’s TrialKey platform — an engine trained on over 450,000 historical clinical trials to estimate the probability of success — and integrates traditional company and macro fundamentals to identify high-probability, high-impact events. These insights are complemented by deep fundamental research into mechanism of action, competitive landscape, and risk-reward profile, enabling conviction-weighted investment decisions. Designed for wholesale investors, the fund offers a disciplined strategy grounded in predictive analytics, active portfolio management, and rigorous due diligence — transforming complexity into opportunity. |
| Category: | AI |
| URL: | https://aibiotechfund.com |
| Operational Status: | Active |
| ASX Listing Code (if applicable): | |
| Year of Commencement: | |
| Address: | Vic,3181 |
| State: | Victoria |
| Overseas Operations: | No |
| X: | |
| Facebook: | |
| Linkedin: | https://www.linkedin.com/company/ai-biotech-fund/ |
| Founders: |
No items found
|
| Awards won: | |
